New CEO chosen to lead innovative-sugar company DouxMatok
Ari Melamud will lead the company and its global expansion plans following the commercialization of the company’s flagship Incredo Sugar ingredient, a real cane sugar product with 30%-50% less sugar.
DouxMatok (New York), a food tech company commercializing an innovative cane sugar ingredient with reduced sugar content, has appointed a new CEO. Ari Melamud will lead the company and its global expansion plans following commercialization of the company’s flagship Incredo Sugar ingredient, a real cane sugar product with 30%-50% less sugar.
Melamud has over two decades of executive management experience across consumer goods marketing, advertising, and B2B specialty ingredients, including CEO positions at both Kimberley-Clark and Sharon Laboratories.
The company recently released its limited-edition Incredo Spreads product, made with Incredo Sugar. The company describes Incredo Sugar as “a first-of-its-kind sugar-based sugar-reduction solution and the main pillar of a full solution that includes a carefully selected mix of nutritional fibers and proteins.” The company is aiming the ingredient at food manufacturers, food service providers, co-packers, bakeries, and chefs. It is already included in food and snacking products, and labeled as “empowered by Incredo Sugar,” in retail stores in Israel.
“Our disruptive solution can successfully address the global challenge of overconsumption of sugar, and I’m eager to lead the company into this phase of global expansion,” said Melamud in a press release.
Kratom sees impressive sales growth despite its regulatory status and stigma
March 12th 2025Despite its controversy, kratom is a top-selling ingredient that consumers see value in. That said, brands need to work hard to demonstrate safety and quality of kratom products in the absence of legal regulatory status. Will kratom be able to overcome its stigma for even more growth and consumer acceptance?
DOJ asks Utah court to dismiss FTC lawsuit against Xlear Inc.
March 11th 2025On March 10, the DOJ and the defendant filed a stipulation to dismiss with prejudice the lawsuit in which each party agrees “to be responsible for its own costs and fees and agrees that no party shall be responsible to any other party for any fines, costs, fees, or penalties arising from this case.”
HHS announces efforts to eliminate independent conclusion of GRAS
Published: March 11th 2025 | Updated: March 11th 2025U.S. Department of Health and Human Services (HHS) Secretary, Robert F. Kennedy Jr., is directing the acting U.S. Food and Drug Administration’s (FDA) acting commissioner to explore rulemaking that would eliminate the independent conclusion of GRAS provision.
